{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-056807","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.772629+00:00","generated_at":"2026-06-01T00:42:55.904066+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"InMed amends ATM equity offering agreement with H.C. Wainwright","bullets":["Amendment to April 2022 at-the-market offering agreement with H.C. Wainwright & Co.","Settlement cycle updated to T+1 (first trading day) to reflect current market rules.","New data privacy compliance representation added; $50k cap on agent's counsel fees reimbursed.","Company to file a prospectus supplement and deliver customary closing deliverables on June 27, 2024.","Prior letter agreements from October 2023 and June 2024 remain effective unless conflicting with amended ATM."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-056807","json":"https://secwatch.observer/filing/0001213900-24-056807.json","markdown":"https://secwatch.observer/filing/0001213900-24-056807.md","text":"https://secwatch.observer/filing/0001213900-24-056807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024056807/0001213900-24-056807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024056807/ea0208584-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:42:55.904066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}